STF-62247

STF-62247 is a potent Autophagy Inducer. STF-62247 shows selective toxicity and growth inhibition of renal cells lacking VHL; 25-fold greater sensitivity observed for cells with VHL deficiency compared to wild-type (VHL+).

Product information

CAS Number: 315702-99-9

Molecular Weight: 267.35

Formula: C15H13N3S

Synonym:

STF 62247

STF62247

STF-062247

STF 062247

STF062247

Chemical Name: 4-(pyridin-4-yl)-N-m-tolylthiazol-2-amine

Smiles: CC1=CC(=CC=C1)NC1=NC(=CS1)C1C=CN=CC=1

InChiKey: KATNUHQNJGNLPW-UHFFFAOYSA-N

InChi: InChI=1S/C15H13N3S/c1-11-3-2-4-13(9-11)17-15-18-14(10-19-15)12-5-7-16-8-6-12/h2-10H,1H3,(H,17,18)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 53 mg/mL(198.24 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

In vitro, STF-62247 shows cytotoxicity and tumor growth inhibitory activity against wild-type VHL and VHL-deficient renal cell carcinoma (RCC) in a HIF-independent manner with IC50 of 16 μM and 0.625 μM, respectively. Moreover, STF-62247 also leads to cell death by increasing acidification and inducing autophagy in VHL-deficient cells. STF-62247 specifically induces macroautophagy and enhances the fusion of autophagosome and lysosomes to form autolysosomes by interfering with Golgi-endoplasmic reticulum transport in cells that have lost VHL . A recent study shows that induction of autophagy by STF-62247 increases sensitivity of RCC under hypoxic conditions to radiation in a VHL-dependent manner.

In Vivo:

In vivo mouse model, STF-62247 at a dose of 8 mg/kg by intraperitoneal injection significantly reduces tumor growth of VHL-deficient SN12C tumor cells.

References:

1. Anbalagan S, et al. Radiother Oncol. 2012, 103(3), 388-393.
2. Chan DA, et al. Cell Cycle. 2008, 7(19), 2987-2990.
3. Turcotte S, et al. Cancer Cell. 2008, 14(1), 90-102.

Products are for research use only. Not for human use.